Physician profile
David B Laha
NPI 1992783450
$1,143.80
in general payments reported to CMS, 2019-2025
22 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.56 · 2020: $15.69 · 2021: $123 · 2022: $248 · 2023: $347 · 2024: $201 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $228.95 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Kowa Pharmaceuticals America, INC. | $102.74 | 2023 | Seglentis |
| Paratek Pharmaceuticals, INC. | $100.47 | 2021-2024 | Nuzyra |
| Nevro Corp. | $94.54 | 2022-2024 | Senza |
| Organogenesis INC. | $92.09 | 2019-2024 | |
| Abbvie INC. | $77.01 | 2022-2025 | |
| Acumed LLC | $50.20 | 2025 | Acumed |
| Convatec INC. | $44.17 | 2023 | |
| In2bones USA, LLC | $38.96 | 2021 | |
| Boston Scientific Corporation | $36.81 | 2024 | Wavewriter Alpha Prime 16 |
| Nabriva Therapeutics, Plc | $34.08 | 2021-2022 | |
| Depuy Synthes Sales INC. | $32.94 | 2023 | Motoband |
| Integra Lifesciences Corporation | $29.68 | 2019-2023 | Tenoglide |
| Smith+Nephew, INC. | $28.70 | 2021-2023 | Grafix Pl |
| Kerecis Limited | $28.47 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgenex LLC | $22.31 | 2025 | Surmatrix, Pellograft, Renograft |
| Biotissue Holdings INC. | $19.94 | 2023 | |
| Titan Surgical Group, LLC | $19.18 | 2022 | |
| Abbott Laboratories | $18.60 | 2025 | Proclaim |
| Zimmer Biomet Holdings, INC. | $15.69 | 2020 | |
| Melinta Therapeutics, LLC | $15.08 | 2024 | Orbactiv, Kimyrsa |
| Horizon Therapeutics Plc | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Laha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.